Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy

(2010) Daniel Y. C. Heng et al.   CANCER

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

(2010) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer

(2009) Susan Halabi et al.   JOURNAL OF CLINICAL ONCOLOGY

On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm

(2008) Debashis Ghosh   BIOMETRICS

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET